Bentley D P, Williams P
Rheumatol Rehabil. 1982 May;21(2):88-92. doi: 10.1093/rheumatology/21.2.88.
Thirty anaemic patients with active rheumatoid arthritis were each given 800 mg of iron , as iron dextran, intramuscularly over an interval of four weeks. The haemoglobin concentration rose significantly within two months in 26 of the patients but this was followed by a significant fall to the pre-treatment level nine months after treatment. The response to iron therapy was not related to the initial haemoglobin concentration, serum iron concentration, transferrin saturation nor to the amount of storage iron, whether assessed by bone marrow stainable iron or the serum ferritin concentration. There was an unexpected fall in the serum ferritin concentration within the first two months after treatment in half of the patients and this was followed by a rise towards the pre-treatment level during the following seven months, such that there was no apparent addition to the amount of storage iron over the period of the study. The possible mechanisms for these findings are discussed. A response to parenteral iron therapy in patients with active rheumatoid arthritis should not be regarded as evidence of iron deficiency and only by correction of the underlying inflammatory process will lasting improvement in the anaemia be obtained.
30例活动性类风湿关节炎贫血患者,均接受800毫克右旋糖酐铁,在四周内分阶段肌肉注射。26例患者在两个月内血红蛋白浓度显著上升,但在治疗九个月后又显著降至治疗前水平。铁疗法的反应与初始血红蛋白浓度、血清铁浓度、转铁蛋白饱和度以及储存铁量无关,无论通过骨髓可染铁还是血清铁蛋白浓度评估。半数患者在治疗后的头两个月内血清铁蛋白浓度意外下降,随后在接下来的七个月内升至治疗前水平,因此在研究期间储存铁量没有明显增加。讨论了这些发现的可能机制。活动性类风湿关节炎患者对胃肠外铁疗法的反应不应被视为缺铁的证据,只有纠正潜在的炎症过程才能使贫血得到持久改善。